Found: 11
Select item for more details and to access through your institution.
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 4, p. 983, doi. 10.1093/cid/ciad506
- By:
- Publication type:
- Article
Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, n. 6, p. 934, doi. 10.1093/cid/ciy201
- By:
- Publication type:
- Article
Association of CYP2B6 SingleNucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
- Published in:
- Clinical Infectious Diseases, 2018, v. 66, n. 12, p. 1953, doi. 10.1093/cid/cix1051
- By:
- Publication type:
- Article
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 4, p. 528, doi. 10.1093/cid/ciw349
- By:
- Publication type:
- Article
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.
- Published in:
- Open Forum Infectious Diseases, 2018, v. 5, n. 2, p. N.PAG, doi. 10.1093/ofid/ofy001
- By:
- Publication type:
- Article
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study.
- Published in:
- Journal of Viral Hepatitis, 2023, v. 30, n. 3, p. 209, doi. 10.1111/jvh.13764
- By:
- Publication type:
- Article
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 6, p. 770, doi. 10.1111/jvh.13067
- By:
- Publication type:
- Article
STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis.
- Published in:
- European Journal of Immunology, 1999, v. 29, n. 8, p. 2524, doi. 10.1002/(SICI)1521-4141(199908)29:08<2524::AID-IMMU2524>3.0.CO;2-H
- By:
- Publication type:
- Article
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
- Published in:
- Journal of Medical Virology, 2019, v. 91, n. 7, p. 1313, doi. 10.1002/jmv.25454
- By:
- Publication type:
- Article
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.
- Published in:
- 2018
- By:
- Publication type:
- journal article